33 recruiting. 33 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 33 | Recruiting 33 |
| Phase 2 | 15 | Recruiting 15 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis TranspoCART19 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 10 | 2026-09-23 | 2026-10-01 |
| US Zamto-cel Autoimmune Diseases zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | Recruiting | Miltenyi Biomedicine GmbH | 48 | 2026-07-01 | 2026-06-11 |
| PS-002 for the Treatment of IgA Nephropathy in Adults PS-002 - Immunoglobulin A (IgA) Nephropathy | Phase 1 / Phase 2 | Recruiting | Purespring Therapeutics Limited | 32 | 2026-03-30 | 2026-09-09 |
| A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) HB2198 - Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | Hinge Bio | 30 | 2026-03-23 | 2026-03-25 |
| Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. umbilical cord blood CD19-BCMA CAR-T cells infusion - Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 45 | 2026-03-18 | 2026-03-03 |
| SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus Autologous anti-CD19 CAR-T cells, intravenous single infusion at protocol-defined dose level (1 x 10^6 or 3 x 10^6 CAR-positive viable T cells/kg)., Fludarabine, Cyclophosphamide - REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 24 | 2026-03-02 | 2026-04-13 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. MIL116, Matching Placebo - Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 130 | 2026-02-05 | 2026-04-13 |
| Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis Vonsetamig, Odronextamab - Lupus Nephritis (LN) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2025-12-22 | 2026-10-27 |
| Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment. - Refractory Membranous Nephropathy | Phase 1 | Recruiting | The First Affiliated Hospital of Air Force Medicial University | 5 | 2025-12-08 | 2025-12-24 |
| A Phase 1 Study of CLYM116 in Normal Healthy Volunteers CLYM116, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Climb Bio, Inc. | 48 | 2025-12-02 | 2026-02-20 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2025-12-01 | 2026-02-03 |
| An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus, Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-24 | 2026-03-04 |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease ALLO-329, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy | Phase 1 | Recruiting | Allogene Therapeutics | 66 | 2025-11-13 | 2026-11-02 |
| UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis UB-VV410 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Recruiting | Nanjing IASO Biotechnology Co., Ltd. | 21 | 2025-10-27 | 2026-01-23 |
| A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases BMS-986515, Fludarabine, Cyclophosphamide - Refractory Autoimmune Diseases | Phase 1 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 125 | 2025-09-04 | 2026-07-14 |
| A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-13 | 2026-10-21 |
| A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-04 | 2026-10-21 |
| Study of BHV-1400 in IgA Nephropathy BHV-1400 - IgA Nephropathy | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 20 | 2025-07-30 | 2026-06-23 |
| CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus CART19 - SLE, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 24 | 2025-05-06 | 2026-09-24 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE AZD0120, Cyclophosphamide, Fludarabine - Lupus Erythematosus, Systemic | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 150 | 2025-04-21 | 2026-09-10 |
Showing 20 of 33. Sign in to see all of them.
Lupus Nephritis (25) · Lupus Erythematosus, Systemic (19) · Autoimmune Diseases (12) · Scleroderma, Systemic (11) · Myositis (8) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (7) · Glomerulonephritis, IGA (5) · Scleroderma, Diffuse (4) · Antiphospholipid Syndrome (3) · Dermatomyositis (2) · Glomerulosclerosis, Focal Segmental (2) · Immune System Diseases (2) · Kidney Diseases (2) · Nephritis (2)
Female Urogenital Diseases (33) · Female Urogenital Diseases and Pregnancy Complications (33) · Male Urogenital Diseases (33) · Urogenital Diseases (33) · Urologic Diseases (32) · Kidney Diseases (31) · Nephritis (31) · Immune System Diseases (30) · Skin and Connective Tissue Diseases (26) · Connective Tissue Diseases (25) · Autoimmune Diseases (20) · Skin Diseases (13) · Muscular Diseases (8) · Nervous System Diseases (8)
Cyclophosphamide (9) · fludarabine (8) · Rituximab (2) · fludarabine phosphate (2) · Bendamustine Hydrochloride (1) · CTL019 chimeric antigen receptor (1) · Kidney Transplantation (1) · Melphalan (1) · Metformin (1) · Standard of Care (1) · Whole-Body Irradiation (1) · tafasitamab (1) · tocilizumab (1)
Beijing GoBroad Hospital (3) · China Immunotech (Beijing) Biotechnology Co., Ltd. (3) · Alice Bertaina (1) · Allogene Therapeutics (1) · AstraZeneca (1) · Beijing Biotech (1) · Beijing Mabworks Biotech Co., Ltd. (1) · Biohaven Therapeutics Ltd. (1) · CRISPR Therapeutics (1) · Cabaletta Bio (1) · Children's Hospital of Philadelphia (1) · Climb Bio, Inc. (1) · Essen Biotech (1) · Fate Therapeutics (1) · Guangdong Provincial People's Hospital (1)
China (15) · United States (15) · Australia (5) · Spain (5) · United Kingdom (4) · Canada (3) · France (3) · Germany (3) · Brazil (1) · Czechia (1) · Israel (1) · Poland (1) · Puerto Rico (1) · Romania (1) · South Korea (1)
Alberto Ortiz Arduan (1) · Alice Bertaina, MD (1) · Caitlin Elgarten, MD (1) · Chitra Hosing, MD (1) · Cijiang He (1) · Esther Eromosele, MD (1) · Huijuan Mao, Doctor (1) · Madhav Menon, MD (1) · Paul Grimm, MD (1) · Xueqing Yu (1)
2025 (2)